Psoriasis Research Today is a free monthly online journal that collates and summarizes the latest research about Psoriasis, including details on treatment, prevention, medication, causes.

High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis.

Rahman P, Roslin NM, Pellett FJ, Lemire M, Greenwood CM, Beyene J, Pope A, Peddle L, Paterson AD, Uddin M, Gladman DD

Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Research Institute, Toronto Western Hospital, 399 Bathurst Street, 1E-410B, Toronto, Ontario M5T 2S8, Canada.

Published 4 March 2011 in Ann Rheum Dis, 70(4): 690-4.
Full-text of this article is available online (may require subscription).

Articles on Psoriasis published 22 February 2011:

Psoriatic arthritis: update on pathophysiology, assessment and management.   Ann Rheum Dis, 70: i77-84.

Psoriatic arthritis (PsA) is classified as a spondyloarthropathy and characterised by synovitis, enthesitis, dactylitis and spondylitis usually manifesting as skin and nail psoriasis. Our understanding about the PsA disease state, its genetics, pathophysiology and comorbidities, as well as the ability to assess and treat the disease, has advanced as a result of significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures ... [Abstract] [Full-text]

The early phase of psoriatic arthritis.   Ann Rheum Dis, 70: i71-6.

Evaluation of the preclinical phases of the classic autoimmune diseases including rheumatoid arthritis has been facilitated by the availability of autoantibody and genetic markers that point firmly towards the early dysregulation of the adaptive immune responses. The association of psoriatic disease with the human leucocyte antigen-Cw0602 (HLA-Cw0602) gene has likewise led to the perception that autoimmunity has a pivotal role in early psoriatic arthritis (PsA). However, this HLA-Cw0602 genetic ... [Abstract] [Full-text]

Articles on Psoriasis published 14 February 2011:

Increased risk of acute myocardial infarction in patients with psoriasis: a 5-year population-based study in Taiwan.   J Am Acad Dermatol, 64(3): 495-501.

[Abstract] [Full-text]

Articles on Psoriasis published 10 January 2011:

Steroid synthesis by primary human keratinocytes; implications for skin disease.   Biochem Biophys Res Commun, 404(1): 62-7.

Cortisol-based therapy is one of the most potent anti-inflammatory treatments available for skin conditions including psoriasis and atopic dermatitis. Previous studies have investigated the steroidogenic capabilities of keratinocytes, though none have demonstrated that these skin cells, which form up to 90% of the epidermis are able to synthesise cortisol. Here we demonstrate that primary human keratinocytes (PHK) express all the elements required for cortisol steroidogenesis and metabolise ... [Abstract] [Full-text]

Articles on Psoriasis published 5 January 2011:

Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.   J Clin Invest, 121(1): 410-21.

Dysregulated angiogenesis is a hallmark of chronic inflammatory diseases, including psoriasis, a common skin disorder that affects approximately 2% of the population. Studying both human psoriasis in 2 complementary xenotransplantation models and psoriasis-like skin lesions in transgenic mice with epidermal expression of human TGF-β1, we have demonstrated that antiangiogenic non-viral somatic gene therapy reduces the cutaneous microvasculature and alleviates chronic inflammatory skin ... [Abstract] [Full-text]

Articles on Psoriasis published 20 December 2010:

Psoriasis and pregnancy outcomes: a nationwide population-based study.   J Am Acad Dermatol, 64(1): 71-7.

[Abstract] [Full-text]

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial.   J Am Acad Dermatol, 64(1): 64-70.

[Abstract] [Full-text]

Articles on Psoriasis published 15 December 2010:

Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor.   J Invest Dermatol, 131(1): 108-17.

Epidermal keratinocytes in psoriatic lesions are characterized by activated Stat3, and increased levels of cytokines and growth factors that promote Stat3 activation have been found within psoriatic lesions. K5.Stat3C transgenic mice, in which keratinocytes express a constitutively active Stat3, develop psoriasis-like skin lesions. In this study, we examined whether STA-21, a small Stat3 inhibitor, could be useful in ameliorating the skin lesions not only in the model mouse but also in human ... [Abstract] [Full-text]

© 2004-2011 Psoriasis Research Today. All Rights Reserved.